Aldeyra (ALDX) announced that the FDA has accepted for review the resubmitted new drug application for topical ocular reproxalap, an investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act target action date of December 16.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion
- Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191
- Aldeyra receives special protocol assessment agreement letter from FDA
- Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
- Aldeyra Resubmits Reproxalap NDA to FDA